Kornimate/medical-research-clean huggingface dataset:
remote ischemic preconditioning in acs patients

Conditions: Acute Coronary Syndrome; Renal Insufficiency; Ischemia, Myocardial

Summary: remote ischemic preconditioning is a process of serial blood pressure cuff inflations and deflations that are performed prior to a procedure and have been shown in various other areas (coronary bypass surgery, vascular surgery, st elevation myocardial infarctions) to decrease the rates of adverse events related to ischemic burden and renal injury. this procedure has not yet been studied in the population presenting with an acute coronary syndrome (acs), even though acs patients represent the majority of patients seen in the catheterization lab. the purpose of this study is to evaluate the efficacy of this simple and safe procedure in this particular population.


Eligibility criteria:
inclusion criteria: - presenting with an acute coronary syndrome including non-st elevation myocardial infarction or unstable angina on optimal medical therapy with aspirin, p2y12 inhibitors, unfractionated heparin, statin, +/- beta blocker, +/- ace inhibitor exclusion criteria: * presenting with st elevation myocardial infarction * patients requiring circulatory support * need for emergent percutaneous coronary intervention * systemic hypotension (systolic blood pressure \<90 mmhg) * patients in cardiogenic shock defined by requiring inotropes or vasopressors * patients currently on hemodialysis * presence of an arteriovenous dialysis fistula or graft or lymphedema in either arm * patients enrolled in other active cardiovascular investigational studies * severe comorbidities with a life expectancy of less than 6 months * pregnant or lactating women * patients unable to provide consent * patient taking the medication glibenclamide for treatment of diabetes
impact of gwg tool on patient knowledge

Conditions: Weight Gain; Pregnancy Related

Summary: women with singleton pregnancies at one outpatient clinic to be recruited for controlled clinical trial. over eight weeks, women 15 0/7--22 6/7 weeks' with at least one prior prenatal visit to be enrolled in the control group. women 6 0/7--14 6/7 weeks' to be enrolled in the intervention group at their first prenatal visit and to receive a pregnancy-specific gestational weight gain card. women to be encouraged to record their weight at each prenatal care visit. all women to complete a gwg knowledge--based questionnaire at 15 0/7-22 6/7 weeks'.


Eligibility criteria:
inclusion criteria: * singleton gestation * primary prenatal care at metrohealth medical center * planning to deliver at metrohealth medical center exclusion criteria: * any inclusion criteria not met * prior diagnosis of eating disorder * inadequate knowledge of english language

Keywords: pregnancy gestational weight gain weight gain patient education patient knowledge institute of medicine
study of 323u66 sr in major depressive disorder

Conditions: Depressive Disorder

Summary: this study was designed to evaluate the efficacy and safety in major depressive disorder patients.


Eligibility criteria:
inclusion criteria: * met dsm-iv-tr criteria for major depressive disorder for their current episode for at least 8 weeks prior to screening visit. * must give a written informed consent. but if the patient is under 20, both the patient himself/herself and his/her proxy consenter must give written informed consent. * must have rating scores as outlined. exclusion criteria: * current or past history of seizure disorder or brain injury. * current or past history of anorexia or bulimia nervosa. * history of manic episode. * past or current dsm- iv-tr diagnosis of schizophrenia or other psychotic disorder. * diagnosis of substance abuse (alcohol or drug) by the dsm-iv-tr criteria. * pregnant, possibly pregnant or lactating. * must not be suicidal. * blood pressure of sbp\>160mmhg, dbp\>100mmhg. * history or complication of cancer or malignant tumour.

Keywords: mdd
efficacy and safety of tideglusib in congenital myotonic dystrophy

Conditions: Congenital Myotonic Dystrophy

Summary: this is a randomized, multicenter, double-blind, placebo-controlled, phase 2/3 study of patients (aged 6 to 16 years) diagnosed with congenital myotonic dystrophy (congenital dm1).

this is a randomized, double-blind, placebo controlled study of weight adjusted dose 1000 mg/day tideglusib versus placebo in the treatment of children and adolescents 6-16 years of age with congenital dm1.

Eligibility criteria:
inclusion criteria: 1. male or female children and adolescents aged ≥6 years and ≤16 years 2. diagnosis of congenital dm1 (also known as steinert's disease) * diagnosis must be genetically confirmed * one or more of the following clinically relevant (e.g. requiring medical intervention) signs or symptoms was evident within the first month after birth: * hypotonia * generalized weakness * respiratory insufficiency * feeding difficulties * clubfoot or another musculoskeletal deformity 3. subject must be able to walk and complete the 10-meter walk-run test (orthotics/splints allowed, forearm crutches are not allowed) 4. written, voluntary informed consent must be obtained before any study related procedures are conducted. * where a parent or lar provides consent, there must also be assent from the subject 5. subject's caregiver must be willing and able to support participation for duration of study 6. subject must be willing and able to comply with the required food intake restrictions as outlined per protocol exclusion criteria: 1. not able to walk; (full time wheel chair use) 2. body mass index (bmi) less than 13.5 kg/m² or greater than 40 kg/m² 3. new or change in medications/therapies within 4 weeks prior to screening 4. use of strong cyp3a4 inhibitors (e.g clarithromycin, telithromycin, ketoconazole, itraconazole, posaconazole, nefazodone, idinavir and ritonavir) within 4 weeks prior to baseline 5. concurrent use of drugs metabolized by cyp3a4 with a narrow therapeutic window (e.g. warfarin and digitoxin) 6. current enrollment in a clinical trial of an investigational drug or enrollment in a clinical trial of an investigational drug in the last 6 months 7. existing or historical medical conditions or complications (e.g. neurological, cardiovascular, renal, hepatic, endocrine, gastrointestinal or respiratory disease) which would cause the investigator to conclude that the subject will not be able to perform the study procedures or assessments or would confound interpretation of data obtained during assessment 8. hypersensitivity to tideglusib and its excipients including allergy to strawberry

Keywords: tideglusib amo-02-md-2-003 congenital myotonic dystrophy myotonic dystrophy dystrophia myotonica myotonia atrophica myotonia dystrophica myotonic dystrophy, congenital steinert disease steinert myotonic dystrophy steinert's disease
trimester sequential estimation of serum zonulin as a predictor of gestational diabetes mellitus

Conditions: Gestational Diabetes

Summary: gestational diabetes mellitus (gdm) is the development of glucose intolerance (gi) during pregnancy in a previously normoglycemic (ng) woman and associated with insulin resistance (ir). gdm is the most prevalent metabolic disorder during pregnancy and became a major public health problem for being usually diagnosed and detected after 24 gestational weeks (gw), while its complications can occur much earlier and this may explain its burden on maternal and fetal welfare. human zonulin is a surrogate marker of intestinal permeability and can be utilized as biomarker for intestinal barrier function. zonulin-mediated increase in intestinal permeability plays a role in the pathogenesis of insulin resistance, obesity, dm and metabolic syndrome. the increasing global prevalence of gdm with its associated risk of poor pregnancy and long-term risks for the mother and the offspring may lead to the production of new generation of diabetics.


Eligibility criteria:
inclusion criteria: * pregnant women with singleton fetus exclusion criteria: * women with morbid obesity with body mass index ≥35 kg/m2; * had manifest dm, irrespective of being controlled or not; * bowel-related disorders; * autoimmune disorders; * history of previous gdm.
performance of a remote monitoring program for patients diagnosed with covid-19

Conditions: Covid19; Infectious Disease; SARS-CoV Infection

Summary: the gw medical faculty associates recently launched a remote monitoring program for patients diagnosed with covid-19. patients are provided with a home pulse oximeter and thermometer. participants complete daily surveys about their symptoms and vital signs and are escalated to receive phone calls and video visits if responses are abnormal. investigators would like to complete a study of the program to understand: 1. operational parameters of program performance, such as how many patients were enrolled and how many patients completed monitoring 2. clinical course of patients, including their reported symptoms over time and clinical endpoints such as hospitalization or icu admission 3. patient satisfaction with program

the sars-cov-2 that emerged in late 2019 has been noted to have a wide range of presentations, from asymptomatic and mild cases to those requiring intubation, ecmo, and critical care. as it is a novel pathogen, clinicians and scientists are only beginning understand when and who will require hospital-based resources such as oxygen, hospitalization, or icu admission. the medical faculty associates (mfa) covid-19 remote monitoring program (rpm) was developed to provide a daily touchpoint for patients during their covid-19 course, including ready connection to paramedics and physicians when needed. the program was launched with the goal of identifying clinical decompensation early, maximizing available healthcare capacity, and minimizing nosocomial covid-19 spread and healthcare worker exposure. investigators would like to perform analyses to test multiple hypotheses, including: 1. patients discharged with a diagnosis of covid-19 will be able to participate in a remote monitoring program. 2. a covid-19 remote monitoring program will benefit patients. 3. patients will be satisfied with their experience of a remote monitoring program and will have lower anxiety about their covid-19 illness.

Eligibility criteria:
inclusion criteria: * laboratory-confirmed coronavirus infection * age \>=18 * primary language english or spanish exclusion criteria: * dementia * pregnant \> 16 weeks gestation

Keywords: covid-19 emergency medicine remote patient monitoring
swe in assessment of ckd patients

Conditions: Elastography ,CKD Patients

Summary: elastography is a developing technique to assess tissue elasticity. it is software that can be integrated to the ultrasonography machines. shear wave elastography (swe) is an elastography technique that does not require external pressure on the tissue and supplies quantitative data. it uses real-time short-duration acoustic push pulse to generate shear waves that propagate perpendicular to the main ultrasound beam. when the waves hit the targeted tissue, the tissue is "pushed" in the direction of propagation, causing it to temporarily deform or displace. the ultrasound scanner can monitor the tissue displacement, measuring the time-to-peak displacement and the recovery time. shear wave velocity increases in diseased tissues, which can be significantly stiffer than normal ones. the parameters are expressed in pressure units of kilopascals (kpa) and velocity (m s-1). swe have been used to study breast, thyroid, prostate and liver diseases. however, the application of swe in assessment of renal fibrosis in ckd patients is still unclear.


Eligibility criteria:
inclusion criteria: * the patients are those older than 18 years diagnosed with ckd based on the kdigo (kidney disease improving global outcomes) definition i.e. egfr less than 60 ml/min and/or the presence of markers of kidney damage (pathological albuminuria of at least 30 mg per 24 hours or proteinuria, hematuria, casts) persisting for more than 3 months. exclusion criteria: * patients whose bmi \>35kg/m 2 any condition that precludes visualization of the kidney by ultrasound or transmission of shear waves as pregnancy or marked ascites patients with surgical kidney problems like hydro or pyonephrosis patients unwilling to complete the study. patients with a history of renal replacement therapy (hemodialysis, peritoneal dialysis) , renal transplant, or acute kidney injury within the last 3 months patients with cystic kidney disease patients with renal masses
heme arginate in functional magnetic resonance imaging (fmri)

Conditions: Ischemia-reperfusion Injury

Summary: ischemia reperfusion injury may be attenuated by ho-1 induction. heme arginate showed protective effects during prolonged ischemia in animal studies. functional blood oxygen level dependent (bold) magnetic resonance imaging (mri) shall evaluate the effects of ho-1 induction during short-time ischemia in skeletal muscle of healthy subjects.

ischemia reperfusion injury may be attenuated by ho-1 induction. heme arginate showed protective effects during prolonged ischemia in animal studies. the investigators previous data confirmed strong ho-1 induction following heme arginate infusion in healthy humans. therefore, the investigators next approach is to evaluate the direct effects of heme arginate on short time ischemia-reperfusion (ir) injury in healthy humans. this will be done by the following surrogate markers of ir injury. functional blood oxygen level dependent (bold) magnetic resonance imaging (mri) can measure alterations in tissue oxygenation in a high spatial and temporal resolution. this non-invasive methods therefore represent a promising technique to evaluate the effects of ho-1 induction on energy metabolism and oxygen saturation during ischemic stress and short time reperfusion in skeletal muscle. as additional outcome, levels of myoglobin and creatine-kinase will be measured in plasma according to standard laboratory procedures.

Eligibility criteria:
inclusion criteria: * signed informed consent * men aged between 18 and 46 years (inclusive) * nonsmoker for more than 3 months * body mass index between 18 and 27 kg/m2 * normal findings in medical history and physical examination unless the investigator considers an abnormality to be clinically irrelevant * negative results from urine drug screen if performed * ability to communicate well with the investigator in the local language and to understand and comply with the requirements of the study exclusion criteria: * known hypersensitivity to the study drug or any excipients of the drug formulation * regular use of medication, abuse of alcoholic beverages, participation in a clinical trial in the 3 weeks preceding the study * treatment with another investigational drug within 3 weeks prior to screening * history or clinical evidence of any disease and/or existence of any surgical or medical condition, which might interfere with the absorption, distribution, metabolism or excretion of the study drug * evidence of hypertension, pathologic hyperglycemia, hyperlipidemia * treatment in the previous 3 weeks with any drug including over-the-counter drugs (including herbal medicines such as st john's wort) * symptoms of a clinically relevant illness in the 2 weeks before the first study day * blood donation during the previous 3 weeks * any metallic, electric, electronic or magnetic device or object not removable * claustrophobia
a randomized, double-blind, placebo-controlled study of idelalisib in combination with rituximab for previously treated chronic lymphocytic leukemia (cll)

Conditions: Chronic Lymphocytic Leukemia

Summary: this phase 3, randomized, double-blind, placebo-controlled study is to evaluate the effect of idelalisib in combination with rituximab on the onset, magnitude, and duration of tumor control in participants previously treated for chronic lymphocytic leukemia (cll). eligible patients will be randomized with a 1:1 ratio into 1 of the 2 treatment arms to receive either idelalisib plus rituximab or placebo plus rituximab. participants who are tolerating primary study therapy but experience definitive cll progression are eligible to receive active idelalisib therapy in the extension study, gs-us-312-0117.


Eligibility criteria:
inclusion: * adult subjects with previously treated recurrent cll who have measurable lymphadenopathy * require therapy for cll * have experienced cll progression \< 24 months since the completion of the last prior therapy * currently not sufficiently fit to receive cytotoxic therapy because of chemotherapy-induced bone marrow damage or comorbidities.

Keywords: cll cal-101 gs 1101 pi3k gs-us-312-0117 idelalisib
functional gi disease registry

Conditions: Functional Gastrointestinal Disorders

Summary: the goal of this study is to establish a prospective observational cohort of individuals with functional gi disorders (functional constipation, irritable bowel syndrome, chronic nausea, functional diarrhea, and functional dyspepsia, as well as a subset of these individuals starting neuromodulation for their functional gi disorder) and collect clinical information and specimens. this information will be used in order to establish a patient registry with detailed clinical data and a specimen repository for future research as well as to specifically identify environmental, genetic, physiological, and psycho-social factors associated with functional gi disorders.


Eligibility criteria:
inclusion criteria: * 18 years of age or older * rome iv criteria for a functional gi disorder exclusion criteria: * acute illness * known bleeding disorder * awaiting transplantation * known diagnosis of inflammatory bowel disease * use of antibiotics in last 2 months
optimization of serum phosphorus level and weaning from mechanical ventilation

Conditions: Mechanical Ventilation

Summary: the goal of this clinical trial is to test the impact of serum phosphorus level optimization on weaning from mechanical ventilation in adult icu patients in alexandria university hospitals. the main questions it aims to answer are: * does serum phosphorus level optimization affect the duration of mechanical ventilation? * is serum phosphorus level optimization associated with successful weaning from mechanical ventilation? in critically ill patients, phosphorus supplementation is done using sodium glycerophosphate pentahydrate solution.

investigators will document patients' data in terms of independent variables and will randomly allocate the participants into one of the two study groups mentioned below. * control group, defined by maintaining serum phosphorus level at ≥ 2.5 and \< 3.5 mg/dl. * intervention group, defined by optimization of serum phosphorus p to ≥ 3.5 and ≤ 4.5 mg/dl (average 4mg/dl). regression and comparative statistics will be used to determine whether the optimum serum phosphorus level offers a benefit in terms of the duration of mechanical ventilation and the success of weaning from mechanical ventilation.

Eligibility criteria:
inclusion criteria: * adult mechanically ventilated icu patients. * age ≥ 18 years. exclusion criteria: * age \<18 years * hypernatremia * permanent or prolonged mechanical ventilation * hyperphosphatemia which might occur in the following conditions: * chronic kidney disease and end stage renal disease * parathyroid disorders * cancer patients at risk of tumor lysis syndrome * immobility * body weight \< 50 kg

Keywords: mechanical ventilation phosphorus critical illness ventilator weaning
treatment of rotator cuff tears with platelet rich plasma

Conditions: Rotator Cuff Tears; Rotator Cuff Tendinitis

Summary: the purpose of this study is to evaluate the safety and effectiveness of dual platelet rich plasma (prp) injections into the rotator cuff insertion and the area of the tendon proximal to the insertion.

patients who have rotator cuff pathology as established by clinical exam and confirmed with mri and have failed activity modification, will be enrolled in this study. they will receive dual platelet rich plasma (prp) injections, one into the rotator cuff insertion and one into the area of the tendon proximal to the insertion, in one treatment session. prp will be prepared through a double spin technique to create two 4 cc doses for injection. patients will evaluated at 6 months, 1 year and two years for improvement in symptoms.

Eligibility criteria:
inclusion criteria: * rotator cuff pathology established by exam * rotator cuff pathology confirmed with mri. * failure to improve with activity modification and physical therapy * willingness to stop all nsaid medication exclusion criteria: * additional significant shoulder pathology seen on xray or mri including: severe arthritis, significant superior labrum anterior postierior (slap) type ii lesions and intra-articular loose bodies. * shoulder surgery within 6 months. * presence of full thickness rotator cuff tears in patients amenable to surgical repair.
stroke rehabilitation utilizing therapeutical methods designed for nature environments

Conditions: Stroke; Stress, Psychological; Post Traumatic Stress Disorder; Depression, Anxiety; Loneliness

Summary: outpatient participants with a recent stroke diagnoses receive complimentary rehabilitation. the nature interventions include ergo- and physiotherapeutic and neurocognitive tasks with the support of an psychotherapeutic frame designed to be performed in a nature environment.

patients with an acute stroke are recruited to the study when signing out from the acute hospital care services. the patients are selected randomly into two groups: intervention and control groups in proportions 1:1. during the four-week study period the partipants in the control group are encouraged to maintain light physical activity 1 to 3 times per week with or without company. the research worker contacts the participants every week. in the nature group the research worker organises individual nature visits in the nearby nature twice a week and encourages the participants to go outdoors with a close-one once a week. all interventional contacts in the nature group are performed in a ecopsychotherapeutical frame consisting of ergo- and physiotherapeutic and neurocognitive tasks.

Eligibility criteria:
inclusion criteria: * acute stroke exclusion criteria: * traumatic intracranial bleeding without stroke * a malign, aggressive disease * severe aphasia or incapable of independent decision making

Keywords: stroke rehabilitation social support cognitive functions activity